Goldline Pharmaceutical IPO
GMP, Subscription, Price, Dates & Financial Details
Pharmaceutical & Drugs
Goldline Pharma comprises 42 products catering to a wide range of medical specialties, including Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology. This division focuses on delivering quality formulations for acute and chronic…
Open Date
Tue, 12 May 2026
Close Date
Thu, 14 May 2026
Price Band
₹ 41 – 43
Lot Size
3000
Issue Size
₹ 11.61 Cr
Minimum Investment
₹ 258,000 (6000 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Goldline Pharmaceutical IPO has successfully completed its IPO process and is now listed on BSE SME Platform. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹11.61 Crore, comprising a fresh issue of 27.00 Lakh equity shares aggregating to ₹11.61 Crore.
The Goldline Pharmaceutical IPO remained open for subscription from May 12, 2026, to May 14, 2026. The basis of allotment was finalized on May 15, 2026, and the company's shares were listed on BSE SME Platform on May 19, 2026.
The company had fixed the price band at ₹41 to ₹43 per share, with a lot size of 3000 shares. Retail investors were required to make a minimum investment of ₹258,000 (based on the upper price band) to apply for one lot.
Bigshare Services Pvt Ltd served as the registrar to the issue. Cumulative Capital Private Limited acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Goldline Pharmaceutical Limited is now a publicly listed company on BSE SME Platform. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Goldline Pharmaceutical IPO Timeline (Tentative)
- IPO Open Date
- Tue, 12 May 26
- IPO Close Date
- Thu, 14 May 26
- Basis of Allotment
- Fri, 15 May 26
- Initiation of Refunds
- Mon, 18 May 26
- Credit of Shares to Demat
- Mon, 18 May 26
- Listing Date
- Tue, 19 May 26 — NSE & BSE
Open Date
12 May 2026
Close Date
14 May 2026
Basis Of Allotment
15 May 2026
Listing Date
19 May 2026
IPO Subscription
Check Live Subscription →The Goldline Pharmaceutical IPO has received bids for 1,53,86,88,000 shares against 18,30,000 shares offered, resulting in an overall subscription of 840.81x. the NII category is subscribed 1,662.39x, Retail Investors 881.15x, and QIBs 180.22x. Within the NII category, BNII is subscribed 2,011.14x, while SNII is subscribed 980.75x.
QIB
180.22x
NII
1662.39x
BNII
2011.14x
SNII
980.75x
RII
881.15x
Total
840.81x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 9,00,000 shares, representing 49.18% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 5,40,000 shares (29.51%), while Non-Institutional Investors (NIIs) receive 3,90,000 shares (21.31%).
| Category | Shares Offered | Shares Offered % |
|---|---|---|
| Qualified Institutions | 540,000 | 29.51% |
| Non-Institutional | 390,000 | 21.31% |
| BNII | 258,000 | 14.1% |
| SNII | 132,000 | 7.21% |
| Retail Investors | 900,000 | 49.18% |
| Total | 1,830,000 | 100% |
Financials Details(₹ in Crores)
| Particular | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 27.4 | 26.28 | 22.93 | 19.39 |
| Revenue | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| Net Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserve & Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowings | 9.47 | 11.03 | 11.13 | 10.83 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Goldline Pharmaceutical Limited KPI Information
| Particular | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| ROE % | 21.02 | 35.83 | 31.31 | 0.9 |
| ROCE % | 24.22 | 38.45 | 32.4 | 19.43 |
| Debt / Equity | 1.07 | 1.5 | 2.14 | 3.09 |
| RoNW % | 17.99 | 27.37 | 22.94 | 4.36 |
| Pat Margin % | 10.38 | 10.09 | 7.66 | 1.29 |
Peers Comparison
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| Goldline Pharmaceutical Ltd | 10 | 0.00 | 4.10 | 4.10 | 27.37 | 12.38 |
| Mono Pharmacare Ltd | 10 | 7.57 | 1.75 | 1.75 | 9.90 | 17.66 |
| Chandra Bhagat Pharma Ltd | 10 | 28.94 | 1.14 | 1.14 | 2.86 | 39.72 |
About Goldline Pharmaceutical Limited
Goldline Pharma comprises 42 products catering to a wide range of medical specialties, including Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology. This division focuses on delivering quality formulations for acute and chronic healthcare requ
Go
Goldline Cardinal includes 54 products developed for the specialty healthcare segment. The division primarily serves Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, offering therapies focused on lifestyle
Goldline Aayushman
Goldline Aayushman consists of 18 products designed for Pediatricians, Child Specialists, Neonatologists, and General Practitioners. The division focuses on pediatric and neonatal healthcare solutions aimed at supporting child wellness and development.
Goldline InLife
Goldline InLife offers 22 products catering to Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians. The division is focused on critical care and specialty treatments required in advanced healthcare settings and hospitals.
Goldline Wellness
Goldline Wellness comprises 10 products dedicated to supportive care in cancer therapy and patient wellness management. The division emphasizes improving patient care and quality of life during treatment.
The company follows an asset-light business model and does not manufacture pharmaceutical products directly. Instead, it collaborates with third-party manufacturers who produce medicines based on the company’s market research, product specifications, and quality standards, while ensuring compliance with applicable pharmaceutical regulations.
All products are marketed and sold under the “Goldline” brand through a well-established distribution network comprising distributors, retailers, and wholesalers. The company currently partners with 15 manufacturers and 7 distributors to ensure efficient supply chain management and market reach.
In addition to pharmaceutical marketing and distribution, the company also supports hospitals and healthcare institutions through procurement assistance and material supply services.
Goldline Pharmaceuticals has established its presence across multiple Indian states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Goldline Pharmaceutical IPO Promoters
- Amol Laxmikant Mujumdar
- Swapan Premprakash Khandelwal
Promoters Holding
Holding Pre Issue
79.70%
Holding Post Issue
0.00%
Goldline Pharmaceutical IPO Objective
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company
- General corporate purposes
Goldline Pharmaceutical Limited Address / Contact Details
Goldline Pharmaceutical Ltd. Address
103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, Maharashtra, 440015
Email: info@goldlinepharma.in
Tel: +91 712 278 6666
Website:http://www.goldlinepharma.in/
IPO Snapshot
Goldline Pharmaceutical IPO Lot Size
The Goldline Pharmaceutical IPO has a lot size of 3,000 shares. Retail investors require a minimum investment of ₹2,58,000 by applying for 2 lot (6,000 shares). The maximum application allowed for the retail category is 2 lots (6,000 shares), requiring an investment of ₹2,58,000.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 6,000 | 258,000.00 |
| Retail (Max) | 2 | 6,000 | 258,000.00 |
| S-HNI (Min) | 3 | 9,000 | 387,000.00 |
| S-HNI (Max) | 7 | 21,000 | 903,000.00 |
| B-HNI (Min) | 8 | 24,000 | 1,032,000.00 |
Issue Reservation
- QIB — 29.51%
- NII — 21.31%
- RII — 49.18%
Book Running Lead Managers
- Cumulative Capital Private Limited
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Goldline Pharmaceutical IPO?
Goldline Pharmaceutical IPO is a Book-building IPO with a total issue size of ₹11.61 crore. The Goldline Pharmaceutical IPO price band is ₹41 to 43 per share. The Goldline Pharmaceutical IPO subscription opens on Tue, May 12, 2026, and closes on Thu, May 14, 2026. The Goldline Pharmaceutical IPO will be listed on the BSE. Bigshare Services Pvt Ltd is the registrar for the Goldline Pharmaceutical IPO.
When will the Goldline Pharmaceutical IPO open for subscription?
The Goldline Pharmaceutical IPO opens on Tue, May 12, 2026 and closes on Thu, May 14, 2026
What is Goldline Pharmaceutical IPO Price Band?
Goldline Pharmaceutical IPO Price Band is ₹41 to 43 per share.
What is Goldline Pharmaceutical IPO Lot Size?
Goldline Pharmaceutical IPO lot size is 3000 shares, Retail investors need a minimum investment of ₹258000 based on the upper price band
What is the minimum investment for Goldline Pharmaceutical IPO?
The minimum investment for Goldline Pharmaceutical IPO is ₹258000, based on one lot of 3000 shares at the upper price band of ₹43 per share.
How to apply for Goldline Pharmaceutical IPO?
Investors can apply for the Goldline Pharmaceutical IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Thu, May 14, 2026. The application amount remains blocked until the Goldline Pharmaceutical IPO allotment is finalized.
What is Goldline Pharmaceutical IPO Issue Size?
Goldline Pharmaceutical IPO issue size is ₹11.61 crores.
What is the Goldline Pharmaceutical IPO Allotment Date?
Goldline Pharmaceutical IPO allotment date is Fri, May 15, 2026.
Who is the Goldline Pharmaceutical IPO Registrar?
The registrar for Goldline Pharmaceutical IPO is Bigshare Services Pvt Ltd. Investors can go to Bigshare Services Pvt Ltd website to check Goldline Pharmaceutical IPO allotment status, refund processing, and other IPO-related information.
What is the Goldline Pharmaceutical IPO GMP?
The Goldline Pharmaceutical IPO GMP (Grey Market Premium) is ₹15 as of Tue, May 19, 2026. Based on the upper price band of ₹43 per share, the estimated Goldline Pharmaceutical IPO listing price is ₹58, indicating a potential listing gain of approximately 34.88% over the issue price.
Who is the Goldline Pharmaceutical IPO Lead Manager?
The book-running lead managers (BRLMs) for the Goldline Pharmaceutical IPO are Cumulative Capital Private Limited. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Goldline Pharmaceutical IPO Red Herring Prospectus (RHP).